Want to see VYNE full AI Analyst Report?
VYNE Stock Chart & Stats
$0.58
-$0.38(-8.88%)
At close: 4:00 PM EST
$0.58
-$0.38(-8.88%)
Day’s Range― - ―
52-Week Range$0.28 - $1.60
Previous CloseN/A
Volume117.27K
Average Volume (3M)2.75M
Market Cap
$22.43M
Enterprise Value-$14.11M
Total Cash (Recent Filing)$24.93M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding33,385,056
10 Day Avg. Volume3,707,448
30 Day Avg. Volume2,746,500
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.89
Price to Sales (P/S)43.53
P/FCF Ratio-0.75
Enterprise Value/Market Cap-0.63
Enterprise Value/Revenue-31.09
Enterprise Value/Gross Profit-31.50
Enterprise Value/Ebitda0.65
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.59
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Corporate Transaction And ListingDefinitive all-stock merger with Yarrow Bioscience and planned Nasdaq listing under a new ticker could broaden the investor base and improve liquidity for the combined company.
Pre-closing FinancingPre-closing financing of approximately $200 million in cash provides material resources to advance the combined pipeline and eases near-term funding pressure.
Safety ProfileRepibresib exhibited a manageable safety profile, which supports continued development and may reduce regulatory and investor concerns about tolerability.
Bears Say
Clinical Trial OutcomeMissing the primary endpoint in the Phase 2b vitiligo trial raises questions about the lead candidate's efficacy and may weaken the program's approval prospects.
Program DiscontinuationDiscontinuation of treatment in the extension phase and termination of the Phase 2b trial removes a key development pathway and reduces the company's near-term clinical pipeline.
Strategic Risk And Financing ConcernsIncreased perceived risk around dermatology programs and the BET inhibitor strategy, together with concerns about securing adequate funding, could amplify stock volatility and investor skepticism.
VYNE Therapeutics News
VYNE FAQ
What was VYNE Therapeutics’s price range in the past 12 months?
VYNE Therapeutics lowest stock price was $0.28 and its highest was $1.59 in the past 12 months.
What is VYNE Therapeutics’s market cap?
VYNE Therapeutics’s market cap is $22.43M.
When is VYNE Therapeutics’s upcoming earnings report date?
VYNE Therapeutics’s upcoming earnings report date is Aug 19, 2026 which is in 39 days.
How were VYNE Therapeutics’s earnings last quarter?
VYNE Therapeutics released its earnings results on May 07, 2026. The company reported -$0.084 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.084.
Is VYNE Therapeutics overvalued?
According to Wall Street analysts VYNE Therapeutics’s price is currently Overvalued.
Does VYNE Therapeutics pay dividends?
VYNE Therapeutics does not currently pay dividends.
What is VYNE Therapeutics’s EPS estimate?
VYNE Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VYNE Therapeutics have?
VYNE Therapeutics has 33,385,056 shares outstanding.
What happened to VYNE Therapeutics’s price movement after its last earnings report?
VYNE Therapeutics reported an EPS of -$0.084 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.598%.
Which hedge fund is a major shareholder of VYNE Therapeutics?
Currently, no hedge funds are holding shares in VYNE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VYNE Therapeutics
VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris. Another candidate in its pipeline is FMX114, a combination treatment incorporating tofacitinib, which is currently in early-stage clinical assessment, referred to as a Phase IIa preclinical trial, for addressing mild-to-moderate atopic dermatitis. Additionally, the company is progressing VYN201, a bromodomain and extra-terminal (BET) inhibitor designed to target a range of immuno-inflammatory disorders, notably those affecting the skin. A further asset is VYN202, which comprises BET inhibitor compounds engineered for selective action on bromodomain 2. Established in 2003, the firm was formerly recognized as Menlo Therapeutics Inc. before officially changing its corporate identity to VYNE Therapeutics Inc. in September 2020. The company's principal operations are based in Bridgewater, New Jersey.
Technical Analysis
Ownership Overview
4.24% Insiders
2.28% Mutual Funds
0.10% Other Institutional Investors
92.57% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---